James P. Boylan's most recent trade in Immunome Inc was a trade of 18,864 Director Stock Option (right to buy) done . Disclosure was reported to the exchange on June 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunome Inc | James P. Boylan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 18,864 | 18,864 | - | - | Director Stock Option (right to buy) | |
| Zenas Biopharma Inc. | James P. Boylan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 18,500 | 18,500 | - | - | Stock Option (Right to Buy) | |
| Compass Therapeutics Inc | James P. Boylan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Immunome Inc | James P. Boylan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 11,333 | 11,333 | - | - | Stock option (right to buy) | |
| Compass Therapeutics Inc | James P. Boylan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) |